Cell Pathways/Aventis Nilandron
Executive Summary
Cell Pathways will promote prostate cancer therapy nilutamide to urologists with a 13-rep sales force beginning Sept. 5 under agreement with Aventis. The reps will be Cell Pathways employees but are being hired and trained by Quintiles' contract sales division Innovex. Cell Pathways said it is also developing a sales force targeting managed care organizations. Nilandron has been available since 1996 but Aventis never promoted the product, Cell Pathways said. Nilandron will be Cell Pathways' first marketed product; the firm's familial adenomatous polyposis therapy Aptosyn (exisulind) is under review at FDA with a user fee goal date of Sept. 25. Cell Pathways plans to use the 13 reps to market Aptosyn and to add 31 sales reps dedicated to promoting Aptosyn to GI specialists following approval
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth